# Genetic insights into alcohol-associated liver disease: integrative transcriptome-wide analysis identifies novel susceptibility genes

**Authors:** Qianchang Wang, Zhe Wang, Minzhe Hu, Fangfeng Liu, Zhengjian Wang

PMC · DOI: 10.3389/fmed.2025.1623367 · 2025-07-31

## TL;DR

This study identifies new genes linked to alcohol-related liver disease and suggests one as a potential drug target for future treatments.

## Contribution

The study identifies three novel ALD susceptibility genes and proposes AFF1 as a potential therapeutic target using integrative transcriptome-wide analysis.

## Key findings

- Three ALD susceptibility genes—AFF1, C4orf36, and HSD17B13—were identified and validated.
- HSD17B13 may reduce ALD risk through lipid metabolism and redox balance.
- AFF1 is implicated in transcription regulation and is a potential therapeutic target.

## Abstract

Alcohol-associated liver disease (ALD) is a chronic condition influenced by both genetic and environmental factors. While GWAS has identified ALD-related loci (PNPLA3, MBOAT7, TM6SF2), underlying genetic mechanisms and therapeutic targets remain unclear.

This study utilized the FinnGen R12 dataset (488,982 participants) and GTEx v8 eQTL data to perform a cross-tissue transcriptome-wide association study (TWAS) using UTMOST, with single-tissue validation via FUSION. Gene-level association analysis (MAGMA), Mendelian randomization (MR), and colocalization were applied to evaluate causal links. Functional significance was assessed through GeneMANIA, drug enrichment, and molecular docking analyses.

Three ALD susceptibility genes—AFF1, C4orf36, and HSD17B13—were identified and validated. HSD17B13 may reduce ALD risk via lipid metabolism and redox balance, while AFF1 is implicated in transcription regulation. C4orf36 requires further study. Drug enrichment analysis highlighted AFF1 as a target for beta-D-allopyranose, dexbrompheniramine, and (+)-chelidonine, with molecular docking confirming strong binding potential.

This study identifies AFF1, C4orf36, and HSD17B13 as ALD susceptibility genes, proposing AFF1 as a potential therapeutic target, paving the way for precision medicine in ALD, though further experimental validation is needed to establish their functional relevance.

## Linked entities

- **Genes:** PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339], MBOAT7 (membrane bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7) [NCBI Gene 79143], TM6SF2 (transmembrane 6 superfamily member 2) [NCBI Gene 53345], AFF1 (ALF transcription elongation factor 1) [NCBI Gene 4299], C4orf36 (chromosome 4 open reading frame 36) [NCBI Gene 132989], HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) [NCBI Gene 345275]
- **Chemicals:** beta-D-allopyranose (PubChem CID 448388), dexbrompheniramine (PubChem CID 16960), (+)-chelidonine (PubChem CID 10147)
- **Diseases:** ALD (MONDO:0010247)

## Full-text entities

- **Genes:** HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) [NCBI Gene 345275] {aka FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3}, MBOAT7 (membrane bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7) [NCBI Gene 79143] {aka BB1, LENG4, LPIAT, LPIAT1, LPLAT, LPLAT11}, TM6SF2 (transmembrane 6 superfamily member 2) [NCBI Gene 53345], AFF1 (ALF transcription elongation factor 1) [NCBI Gene 4299] {aka AF4, FEL, MLLT2, PBM1}, C4orf36 (chromosome 4 open reading frame 36) [NCBI Gene 132989], PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339] {aka ADPN, C22orf20, iPLA(2)epsilon}
- **Diseases:** ALD (MESH:D008108)
- **Chemicals:** lipid (MESH:D008055), beta-D-allopyranose (-), dexbrompheniramine (MESH:C015121), (+)-chelidonine (MESH:C062047)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12351384/full.md

---
Source: https://tomesphere.com/paper/PMC12351384